The clinical trial for Moderna’s Covid-19 vaccine designed to protect against the B.1.351 variant, first identified in South Africa, has begun, the US National Institutes of Health said Wednesday.
First shots have been administered as part of Phase 1 of the trial that is taking place in the Atlanta, Cincinnati, Nashville, and Seattle areas.
The trial aims to enroll around 210 participants.
According to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, current available vaccines should be “adequate” against the variant, but NIAID is continuing its work with Moderna on this trial “out of an abundance of caution.”
The variant-specific vaccine is also an mRNA vaccine that targets spike proteins, like Moderna’s original vaccine, but the targeting takes into account the mutations that distinguish the B.1.351 variant.
The trial will be enrolling people who have already received Moderna’s initial vaccine as well as people who are so far unvaccinated. Participants will be split into eight different vaccine cohorts that will test different dosages and combinations. Some participants will receive only the variant-specific vaccine or the general vaccine, while some will be testing a combination regimen of the two.
Recent Comments